LONDON, March 22, 2016 /PRNewswire/ -- A new report from business intelligence provider GBI Research - Alzheimer's Therapeutics in Asia-Pacific Markets to 2021 - states that the Asia-Pacific (APAC) Alzheimer's disease market will grow from $3 billion in 2014 to $5.1 billion in 2021, representing a robust Compound Annual Growth Rate of 7.9%.
The main driver of this impressive growth, which will occur across the APAC countries of India, China, Australia and Japan, will be rising and aging populations, as Alzheimer's disease is significantly more prevalent among the elderly.
Additional market drivers include better diagnostic techniques, improving health awareness, special healthcare programs, health insurance coverage, and increasing treatment affordability.
Ad Statistics
Times Displayed: 22687
Times Visited: 478 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Analyst Gayathri Kanika says: "An example of healthcare reforms is the Japanese government's recently approved plan to increase the number of nurses and care workers in the country's healthcare system by 2025, in order to help patients access and interpret information about their health, thereby improving knowledge and diagnoses of Alzheimer's.
"Across the APAC region, the expansion of health insurance coverage will increase access to healthcare, also leading to a rise in Alzheimer's diagnosis and higher treatment rates."
GBI Research also states that in terms of the current Alzheimer's pipeline, there are a number of late-stage products with the potential to be approved and launched in APAC countries during the forecast period. These include first-in-class Beta-site Amyloid precursor protein Cleaving Enzyme (BACE)1 inhibitors and passive immunotherapies.
Gayathri explains: "Three important anti-beta Amyloid (Aβ) drugs are Roche's gantenerumab, TauRX Therapeutics' LMTX and Merck's MK-8931 (verubecestat), which are in Phase III development in Australia and Japan, and will capture significant market share in these countries after they are launched late in the forecast period.
"Acetylcholinesterase Inhibitors (AChEIs), such as Eisai's Aricept (donepezil), Novartis' Exelon (rivastigmine) and Janssen's Razadyne (galantamine), will also continue to capture major patient share across all Alzheimer's sub-populations in the four APAC countries."
Despite the success of these treatments, GBI Research states that significant unmet needs will remain for Alzheimer's patients as there are only a few disease-modifying therapies in the late stage pipeline, with currently available therapies only able to treat symptoms of the disease rather than preventing or slowing its progression.
Sample pages of GBI Research's report Alzheimer's Therapeutics in Asia-Pacific Markets to 2021 are available upon request
About GBI Research
GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on:
